Drug Profile


Alternative Names: Bio-Flow

Latest Information Update: 04 Oct 2000

Price : $50

At a glance

  • Originator Savient Pharmaceuticals
  • Class Antiplatelets; Ischaemic heart disorder therapies; Peptides
  • Mechanism of Action GPIb receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis; Vascular restenosis

Most Recent Events

  • 04 Oct 2000 Discontinued-Preclinical for Vascular restenosis in USA (Unknown route)
  • 04 Oct 2000 Discontinued-Preclinical for Thrombosis in Israel (Unknown route)
  • 04 Oct 2000 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top